Xilio Therapeutics announces updated Phase 2 data for vilastobart
Xilio Therapeutics (XLO) announced updated data from its ongoing Phase 2 clinical trial evaluating vilastobart, a tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4, in combination with atezolizumab in patients with metastatic MSS CRC. The data will be presented in a poster session at the American Society of Clinical Oncology, ASCO, Annual Meeting in Chicago. Results include: 26% preliminary objective response rate observed in heavily pre-treated patients with metastatic microsatellite stable colorectal cancer without liver metastases; Deep and durable responses ongoing for up to 37 weeks through the data cutoff, accompanied by substantial decreases in tumor biomarkers and improvements in clinical symptoms; MSS CRC patient with liver metastasis and previously reported confirmed partial response from Phase 1C remains on treatment after more than 14 months; combination continued to demonstrate differentiated safety and tolerability profile with low incidence of colitis and other immune-related adverse events
Confident Investing Starts Here:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
FINDELL CAPITAL MANAGEMENT URGES OPORTUN STOCKHOLDERS TO VOTE THE WHITE PROXY CARD TO ELECT AN INDEPENDENT CONSUMER FINANCIAL SERVICES EXPERT TO THE BOARD
NEW YORK, June 3, 2025 /PRNewswire/ -- Findell Capital Management LLC (collectively with its affiliates, "Findell", "we" or "us"), one of the largest stockholders of Oportun Financial Corporation (NASDAQ: OPRT), today issued an open letter to its fellow stockholders. The full text of the letter can be found here: Findell Letter to OPRT Stockholders (June 3, 2025) We urge stockholders to vote on the enclosed WHITE proxy card to: Elect our highly qualified and independent candidate, Warren Wilcox, who is a seasoned director and executive with financial services expertise and fresh ideas for enhancing value. Reelect the newly appointed and highly qualified Carlos Minetti, who, while a minority in a boardroom dominated by inexperience and close ties to CEO Raul Vazquez, has the independence and experience we believe is crucial to delivering value at Oportun. Reject the continued Board service of failed CEO Raul Vazquez to finally provide our directors with an unobstructed forum for evaluating his record, providing long-overdue oversight and considering potential replacements. We, as stockholders, have a fleeting opportunity to mitigate Mr. Vazquez's value-destructive influence at this year's Annual Meeting. The Board's "classified" structure means he may not appear on the ballot again until 2028 or later (even if the Board is declassified at the Annual Meeting, Mr. Vazquez's three-year term would not be reduced). This is the moment to lay a foundation for a lasting turnaround by removing Mr. Vazquez from the Board. Importantly, if you have already voted for Mr. Vazquez on the Company's proxy card by mail, internet or phone, a later-dated vote on the enclosed WHITE proxy card will revoke your prior vote. Only your latest dated vote counts! Visit for information on how to vote. Contact: Findell Capital Management, LLC88 Pine Street, 22nd York, NY 10005info@ OR Saratoga Proxy Consulting LLCJohn Fergusoninfo@ View original content: SOURCE Findell Capital Management, LLC
Yahoo
2 hours ago
- Yahoo
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective June 1, 2025, the company granted non-qualified stock options to purchase 181,300 shares of its common stock to five new employees under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan. The stock options have an exercise price of $1.07 per share, which is equal to the closing price of the company's common stock on May 30, 2025. Each stock option has a ten-year term and will vest as to 25% of the shares underlying the stock option on the first anniversary following commencement of employment, and the remaining 75% of the shares underlying the stock option will vest in 36 equal monthly installments thereafter, subject to continued service with the company or any of its subsidiaries through each applicable vesting date. The stock options are subject to the terms and conditions of Xilio Therapeutics' 2022 Inducement Stock Incentive Plan, as well as the terms and conditions of the stock option agreement covering the grant and were made as an inducement material to the individual entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). About Xilio TherapeuticsXilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated, or masked, immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is leveraging its proprietary platform to advance a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment. Learn more by visiting and follow us on LinkedIn (Xilio Therapeutics, Inc.). Investor and Media Contact: Scott YoungVice President, Investor Relations and Corporate Communicationsinvestors@ in to access your portfolio
Yahoo
4 hours ago
- Yahoo
ASCO 2025: GSK's Jemperli fails to show OS benefit in 1L advanced ovarian cancer
At the American Society of Clinical Oncology (ASCO) Annual Meeting 2025, held from 31 May to 3 June in Chicago, Illinois, updated efficacy and safety data from the international, double-blind, randomised Phase III FIRST clinical trial were presented on 1 June. The trial evaluated the combination of GSK's Jemperli (dostarlimab), a monoclonal antibody targeting programmed cell death protein 1, and Zejula (niraparib), a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with platinum-based chemotherapy (PtCh) as a first-line therapy in patients with stage III and IV epithelial ovarian cancer (OC). OC is a deadly gynaecological malignancy, with approximately 90% of cases classified as epithelial. According to GlobalData's Ovarian Cancer: Opportunity Assessment and Forecast report, the number of diagnosed incident cases of OC in the seven major markets (7MM: France, Germany, Italy, Japan, Spain, the UK and the US) is expected to rise from 67,762 in 2025 to 71,308 by 2032. In the FIRST/ENGOT-OV44 study, a total of 1,138 patients with advanced OC were randomised (1:1:2) to experimental arm 1 (PtCh + placebo and placebo maintenance; dropped from the study due to PARP inhibitor approval), arm 2 (PtCh + placebo and Zejula maintenance; n=385), and comparator arm 3 (PtCh + Jemperli and Jemperli/Zejula maintenance; n=753). The efficacy of arms 2 and 3 (intention-to-treat population) was evaluated based on the primary endpoint - investigator-assessed progression-free survival (PFS). The PFS showed a statistically significant difference between arm 3 and arm 2 (median 20.6 months versus 19.2; hazard ratio [HR] 0.85, 95% confidence interval [CI], 0.73–0.99, P = 0.0351), with a median duration follow-up of 53.1 months. The key secondary endpoint, overall survival (OS), had reached 57% maturity and was not statistically significant (median 44.4 versus 45.4 months; HR 1.01, 95% CI, 0.86–1.19, P = 0.9060). In the maintenance period, treatment-related adverse events above Grade 3 were reported in 41.1% of patients in arm 3 and 37.2% in arm 2. The study concludes that adding Jemperli to PtCh and Zejula provides a statistically significant but clinically modest PFS benefit, with no improvement in OS for newly diagnosed advanced OC patients. The result was not unexpected, as immune checkpoint inhibitors have shown limited efficacy in OC, which is considered poorly immunogenic. At the end of 2024, Merck & Co's Keytruda (pembrolizumab) and AstraZeneca's Lynparza (olaparib) also failed to meet expectations in the KEYLYNK-001 study as a first-line therapy for OC, showing no OS benefit, similar to findings from the FIRST/ENGOT-OV44 study. Currently, no anti-PD-(L)1 therapies are approved for OC, and demonstrating a positive OS outcome is critical to gaining market share in this broad indication. A key difference between the two studies lies in patient selection. KEYLYNK-001 enrolled patients with breast cancer gene (BRCA) mutations, whereas the FIRST/ENGOT-OV44 trial included all-comers. To improve its chances of success, GSK made multiple modifications to the FIRST/ENGOT-OV44 trial design, including delaying readouts by several years. Initially, the primary endpoint was PFS in PD-L1-positive patients. In 2020, it was split into two groups, PFS in all-comers and PD-L1 expressers, before ultimately shifting the focus solely to all-comers. Another concern is the Jemperli and Zejula combination in the second-line setting for OC. A Phase III trial (NSGO-AVATAR) evaluating this combination was withdrawn due to a lack of financial support, suggesting GSK may not be optimistic about its prospects in the broader gynaecological cancer space. According to GlobalData's analyst consensus forecast, global sales for Jemperli and Zejula are projected to reach $2.56 billion and $1.26 billion, respectively, by 2030. In comparison, AstraZeneca's Lynparza and blockbuster PD-1 blocker Merck's Keytruda are expected to reach global sales of $2.4 billion and $22.71 billion, respectively. GSK acquired both Jemperli (co-developed with AnaptysBio) and Zejula through its $5.31 billion acquisition of Tesaro in 2019. After the FDA's accelerated approval in 2021 for patients with mismatch repair-deficient endometrial cancer as a second-line treatment, Jemperli has become a cornerstone of GSK's cancer portfolio alongside Zejula. In its most recent financial report, Jemperli sales increased 15% to $285 million in Q1 2025 due to broad-label expansion in first-line endometrial cancer regardless of biomarker status in the US. However, Jemperli holds a distinct advantage with its OS data over its main competitor, Keytruda, which also secured broad expansion in 2024. To expand Jemperli's success beyond endometrial cancer, GSK will need to wait for positive Phase III results from other ongoing clinical trials: GALAXIES LUNG 301, AZUR-2, MITO 33, JADE, ROCSAN and COSTAR Lung. "ASCO 2025: GSK's Jemperli fails to show OS benefit in 1L advanced ovarian cancer" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
